Calcium phosphate nanoparticles as a new generation vaccine adjuvant

References

• Chan EH, Brewer TF, Madoff LC, et al. Global capacity for emerging infectious disease detection. P Natl Acad Sci USA. 2010;107(50):21701–21706.
   PubMed Web of Science ®Google Scholar
• Taki A, Smooker P. Small wonders—the use of nanoparticles for delivering antigen. Vaccines. 2015;3(3):638–661.
   Web of Science ®Google Scholar
• Maughan CN, Preston SG, Williams GR. Particulate inorganic adjuvants: recent developments and future outlook. J Pharm Pharmacol. 2015;67(3):426–449.
   PubMed Web of Science ®Google Scholar
• Doherty M, Buchy P, Standaert B, et al. Vaccine impact: benefits for human health. Vaccine. 2016;34(52):6707–6714.
   PubMed Web of Science ®Google Scholar
• Rappuoli R, Mandl CW, Black S, et al. Vaccines for the twenty-first century society. Nat Rev Immunol. 2011;11(12):865–872.
   PubMed Web of Science ®Google Scholar
• Hamborsky J, Kroger A. Epidemiology and prevention of vaccine-preventable diseases. E-Book: The Pink Book. Public Health Foundation, 2015:231–246.
   Google Scholar
• Amanna IJ, Slifka MK. Contributions of humoral and cellular immunity to vaccine-induced protection in humans. Virology. 2011;411(2):206–215.
   PubMed Web of Science ®Google Scholar
• Pasquale AD, Preiss S, Silva FTD, et al. Vaccine adjuvants: from 1920 to 2015 and beyond. Vaccines. 2015;3(2):320–343.
   PubMed Web of Science ®Google Scholar
• Schijns VE, Lavelle EC. Trends in vaccine adjuvants. Expert Rev Vaccines. 2011;10(4):539–550.
   PubMed Web of Science ®Google Scholar
• Gupta A, Das S, Schanen B, et al. Adjuvants in micro- to nanoscale: current state and future direction. Wires Nanomed Nanobi. 2015;8(1):61–84.
   PubMed Web of Science ®Google Scholar
• Garçon N, Leroux Roels G, Cheng WF. Vaccine adjuvants. Perspect Vaccinology. 2011;1(1):89–113.
   Google Scholar
• Gutjahr A, Tiraby G, Perouzel E, et al. Triggering intracellular receptors for vaccine adjuvantation. Trends Immunol. 2016;37(9):573–587.
   PubMed Web of Science ®Google Scholar
• Glenny AT, Pope CG, Hilda W, et al. Immunological notes. XVII-XXIV. J Pathol Bacteriol. 1926;29(1):31–40.
   Google Scholar
• Powell BS, Andrianov AK, Fusco PC. Polyionic vaccine adjuvants: another look at aluminum salts and polyelectrolytes. Clin Exp Vaccine Res. 2015;4(1):23–45.
   PubMed Web of Science ®Google Scholar
• Reed SG, Bertholet S, Coler RN, et al. New horizons in adjuvants for vaccine development. Trends Immunol. 2009;30(1):23–32.
   PubMed Web of Science ®Google Scholar
• Zhu YZ, Liu DW, Liu ZY, et al. impact of aluminum exposure on the immune system: a mini review. Environ Toxicol Phar. 2013;35(1):82–87.
   PubMed Web of Science ®Google Scholar
• Chowdhury R. A review on the application of nanotechnology in pharmaceutical science. EWU Institutional Repository. 2015-08-06. Available from: http://dspace.ewubd.edu/handle/123456789/1634
   Google Scholar
• Cruz LJ, Rosalia RA, Kleinovink JW, et al. Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8(+) T cell response: a comparative study. J Control Release. 2014;192(7):209–218.
   PubMed Web of Science ®Google Scholar
• Marrache S, Tundup S, Harn DA, et al. Ex vivo programming of dendritic cells by mitochondria-targeted nanoparticles to produce interferon-gamma for cancer immunotherapy. Acs Nano. 2013;7(8):7392–7402.
   PubMed Web of Science ®Google Scholar
• Park JH, Maltzahn GV, Zhang L, et al. Systematic surface engineering of magnetic nanowoms for in vivo tumor targeting. Small. 2009;5(6):694–700.
   PubMed Web of Science ®Google Scholar
• Gregory AE, Titball R, Williamson D. Vaccine delivery using nanoparticles. Front Cell Infect Mi. 2013;3(1):13–13.
   PubMed Web of Science ®Google Scholar
• Liu Y, Xu Y, Tian Y, et al. Functional nanomaterials can optimize the efficacy of vaccines. Small. 2014;10(22):4505–4520.
   PubMed Web of Science ®Google Scholar
• Smith JD, Morton LD, Ulery BD. Nanoparticles as synthetic vaccines. Curr Opin Biotech. 2015;34:217–224.
   PubMed Web of Science ®Google Scholar
• Sharma S, Verma A, Teja BV, et al. An insight into functionalized calcium based inorganic nanomaterials in biomedicine: trends and transitions. Colloid Surface B. 2015;133:120–139.
   PubMed Web of Science ®Google Scholar
• Epple M, Ganesan K, Heumann R, et al. Application of calcium phosphate nanoparticles in biomedicine. J Mater Chem. 2010;20(1):18–23.
   Web of Science ®Google Scholar
• Uskoković V, Wu VM. Calcium phosphate as a key material for socially responsible tissue engineering. Materials. 2016;9(6):434.
   PubMed Web of Science ®Google Scholar
• Chu W, Huang Y, Yang C, et al. Calcium phosphate nanoparticles functionalized with alendronate-conjugated polyethylene glycol (PEG) for the treatment of bone metastasis. Int J Pharmaceut. 2017;516(1–2):352–363.
   PubMed Web of Science ®Google Scholar
• Chen F, Zhu YJ, Zhang KH, et al. Europium-doped amorphous calcium phosphate porous nanospheres: preparation and application as luminescent drug carriers. Nanoscale Res Lett. 2011;6(1):67.
   PubMed Web of Science ®Google Scholar
• Jiang D, Premachandra GS, Johnston C, et al. Structure and adsorption properties of commercial calcium phosphate adjuvant. Vaccine. 2004;23(5):693–698.
   PubMed Web of Science ®Google Scholar
• Gupta RK, Siber GR. Adjuvants for human vaccines-current status, problems and future prospects. Vaccine. 1995;13(14):1263–1276.
   PubMed Web of Science ®Google Scholar
• Goto N, Kato H, Maeyama JI, et al. Local tissue irritating effects and adjuvant activities of calcium phosphate and aluminium hydroxide with different physical properties. Vaccine. 1997;15(12):1364–1371.
   PubMed Web of Science ®Google Scholar
• Masson JD, Thibaudon M, Bélec L, et al. Calcium phosphate: a substitute for aluminum adjuvants? Expert Rev Vaccines. 2017;16: 289–299.
   PubMed Web of Science ®Google Scholar
• Goto N, Kato H, Maeyama J, et al. Studies on the toxicities of aluminium hydroxide and calcium phosphate as immunological adjuvants for vaccines. Vaccine. 1993;11(9):914–918.
   PubMed Web of Science ®Google Scholar
• Relyveld EH, Martin R, Raynaud M, et al. Calcium phosphate as adjuvant in vaccinations in man. Ann Inst Pasteur. 1969;116:300–326.
   PubMedGoogle Scholar
• Relyveld EH. Preparation and use of calcium phosphate adsorbed vaccines. Dev Biol Stand. 1986;65(65):131–136.
   PubMedGoogle Scholar
• Olmedo H, Herrera M, Rojas L, et al. Comparison of the adjuvant activity of aluminum hydroxide and calcium phosphate on the antibody response towards Bothrops asper snake venom. J Immunotoxicol. 2013;11(1):44–49.
   PubMed Web of Science ®Google Scholar
• Dorozhkin SV. A detailed history of calcium orthophosphates from 1770s till 1950. Mat Sci Eng C. 2013;33(6):3085–3110.
   PubMed Web of Science ®Google Scholar
• Dorozhkin SV. Amorphous calcium orthophosphates: nature, chemistry and biomedical applications. Int J Mater Chem. 2012;2(1):19–46.
   Google Scholar
• Dorozhkin SV. Calcium orthophosphates(CaPO4): occurrence and properties. Prog Biomater. 2016;5(1):9–70.
   PubMed Web of Science ®Google Scholar
• Jarcho M. Calcium phosphate ceramics as hard tissue prosthetics. Clin Orthop Relat R. 1981;157(157):259–278.
   Google Scholar
• Kwong CH, Burns WB, Cheung HS. Solubilization of hydroxyapatite crystals by murine bone cells, macrophages and fibroblasts. Biomaterials. 1989;10(9):579–584.
   PubMed Web of Science ®Google Scholar
• Bondarenko O, Juganson K, Ivask A, et al. Toxicity of Ag, CuO and ZnO nanoparticles to selected environmentally relevant test organisms and mammalian cells in vitro: a critical review. Arch Toxicol. 2013;87(7):1181–1200.
   PubMed Web of Science ®Google Scholar
• Tang R, Cai Y. Calcium phosphate nanoparticles in biomineralization and biomaterials. J Mater Chem. 2008;18(32):3775–3787.
   Web of Science ®Google Scholar
• Colby AH, Colson YL, Grinstaff MW. Microscopy and tunable resistive pulse sensing characterization of the swelling of pH-responsive, polymeric expansile nanoparticles. Nanoscale. 2013;5(8):3496–3504.
   PubMed Web of Science ®Google Scholar
• Morgan TT, Muddana HS, Altinoglu EI, et al. Encapsulation of organic molecules in calcium phosphate nanocomposite particles for intracellular imaging and drug delivery. Nano Lett. 2008;8(12):4108–4115.
   PubMed Web of Science ®Google Scholar
• Cai S, Yu X, Xiao Z, et al. Synthesis and sintering of nanocrystalline hydroxyapatite powders by gelatin-based precipitation method. Ceram Int. 2007;33(2):193–196.
   Web of Science ®Google Scholar
• Wang Z, Tang Z, Qing F, et al. Applications of calcium phosphate nanoparticles in porous hard tissue engineering scaffolds. Nano. 2012;7(04):1230004.
   Web of Science ®Google Scholar
• Peng M, Kokuryo D, Cabral H, et al. Hydrothermally synthesized PEGylated calcium phosphate nanoparticles incorporating Gd-DTPA for contrast enhanced MRI diagnosis of solid tumors. J Control Release. 2013;174(1):63–71.
   PubMed Web of Science ®Google Scholar
• And SB, Saha SK. Synthesis and characterization of hydroxyapatite nanopowders by emulsion technique. Chem Mater. 2003;15(23):4464–4469.
   Web of Science ®Google Scholar
• Mohn D, Doebelin N, Tadier S, et al. Reactivity of calcium phosphate nanoparticles prepared by flame spray synthesis as precursors for calcium phosphate cements. J Mater Chem. 2011;21(36):13963–13972.
   Web of Science ®Google Scholar
• Shu C, Wang Y, Hong L, et al. Synthesis of carbonated hydroxyapatite nanofibers by mechanochemical methods. Ceram Int. 2005;31(1):135–138.
   Web of Science ®Google Scholar
• Xu JL, Khor KA, Dong ZL, et al. Preparation and characterization of nano-sized hydroxyapatite powders produced in a radio frequency (rf) thermal plasma. Mat Sci Eng A. 2004;374(1):101–108.
   Web of Science ®Google Scholar
• Li B, Chen X, Guo B, et al. Fabrication and cellular biocompatibility of porous carbonated biphasic calcium phosphate ceramics with a nanostructure. Acta Biomater. 2009;5(1):134–143.
   PubMed Web of Science ®Google Scholar
• Castro F, Ribeiro VP, Ferreira A, et al. Continuous-flow precipitation as a route to prepare highly controlled nanohydroxyapatite: in vitro mineralization and biological evaluation. Mater Res Express. 2016;3(7):075404.
   Web of Science ®Google Scholar
• Saeed MI, Omar AR, Hussein MZ, et al. Systemic antibody response to nano-size calcium phosphate biocompatible adjuvant adsorbed HEV-71 killed vaccine. Clin Exp Vaccine Res. 2015;4(1):88–98.
   PubMed Web of Science ®Google Scholar
• Koppad S, Raj GD, Gopinath VP, et al. Calcium phosphate coupled Newcastle disease vaccine elicits humoral and cell mediated immune responses in chickens. Res Vet Sci. 2011;91(3):384–390.
   PubMed Web of Science ®Google Scholar
• He Q, Mitchell AR, Johnson SL, et al. Calcium phosphate nanoparticle adjuvant. Clin Diagn Lab Immunol. 2000;7(6):899–903.
   PubMedGoogle Scholar
• He Q, Mitchell A, Morcol T, et al. Calcium phosphate nanoparticles induce mucosal immunity and protection against herpes simplex virus type 2. Clin Diagn Lab Immunol. 2002;9(5):1021–1024.
   PubMedGoogle Scholar
• Knuschke T, Rotan O, Bayer W, et al. Combination of nanoparticle-based therapeutic vaccination and transient ablation of regulatory T cells enhances anti-viral immunity during chronic retroviral infection. Retrovirology. 2016;13(1):1–11.
   PubMed Web of Science ®Google Scholar
• Behera T, Swain P. Antigen adsorbed calcium phosphate nanoparticles stimulate both innate and adaptive immune response in fish, Labeo rohita H. Cell Immunol. 2011;271(2):350–359.
   PubMed Web of Science ®Google Scholar
• Joyappa DH, Kumar CA, Banumathi N, et al. Calcium phosphate nanoparticle prepared with foot and mouth disease virus P1-3CD gene construct protects mice and guinea pigs against the challenge virus. Vet Microbiol. 2009;139(1):58–66.
   PubMed Web of Science ®Google Scholar
• Rahimi MT, Sarvi S, Sharif M, et al. Immunological evaluation of a DNA cocktail vaccine with co-delivery of calcium phosphate nanoparticles (CaPNs) against the Toxoplasma gondii RH strain in BALB/c mice. Parasitol Res. 2016;116:609616.
   Web of Science ®Google Scholar
• Yan XF, Gao S, Xia JF, et al. Epidemic characteristics of hand, foot, and mouth disease in Shanghai from 2009 to 2010: enterovirus 71 subgenotype C4 as the primary causative agent and a high incidence of mixed infections with coxsackievirus A16. J Infect Dis. 2012;44(4):297–305.
   Web of Science ®Google Scholar
• Yang C, Deng C, Wan J, et al. Neutralizing antibody response in the patients with hand, foot and mouth disease to enterovirus 71 and its clinical implications. Virol J. 2011;8(1):1–6.
   PubMed Web of Science ®Google Scholar
• Alexander DJ. Newcastle disease. Brit Poultry Sci. 2001;42(1):5–22.
   Google Scholar
• Kapczynski DR, Afonso CL, Miller PJ. Immune responses of poultry to Newcastle disease virus. Dev Comp Immunol. 2013;41(3):447–453.
   PubMed Web of Science ®Google Scholar
• Zelinskyy G, Dietze K, Sparwasser T, et al. Regulatory T cells suppress antiviral immune responses and increase viral loads during acute infection with a lymphotropic retrovirus. Plos Pathog. 2009;5(8):e1000406.
   PubMed Web of Science ®Google Scholar
• Fang HM, Ge R, Sin YM. Cloning, characterisation and expression of Aeromonas hydrophila major adhesin. Fish Shellfish Immun. 2004;16(5):645–658.
   PubMed Web of Science ®Google Scholar
• Parida S, Oh Y, Reid SM, et al. Interferon-gamma production in vitro from whole blood of foot-and-mouth disease virus (FMDV) vaccinated and infected cattle after incubation with inactivated FMDV. Vaccine. 2006;24(7):964–969.
   PubMed Web of Science ®Google Scholar
• Doel TR. FMD vaccines. Virus Res. 2003;91(1):81–99.
   PubMed Web of Science ®Google Scholar
• Beard C, Ward G, Rieder E, et al. Development of DNA vaccines for foot-and-mouth disease, evaluation of vaccines encoding replicating and non-replicating nucleic acids in swine. J Biotechnol. 1999;73(2):243–249.
   PubMed Web of Science ®Google Scholar
• Innes EA. Vaccination against Toxoplasma gondii: an increasing priority for collaborative research? Expert Rev Vaccines. 2010;9(10):1117–1119.
   PubMed Web of Science ®Google Scholar
• Zhang NZ, Chen J, Wang M, et al. Vaccines against Toxoplasma gondii: new developments and perspectives. Exp Rev Vaccines. 2013;12(11):1287–1299.
   PubMed Web of Science ®Google Scholar
• Glenny A, Pope C. The antigenic effect of intravenous injection of diphtheria toxin. J Pathol Bacteriol. 1925;28(2):273–278.
   Google Scholar
• Waksman BH, Bullington S. Studies of arthritis and other lesions induced in rats by injection of mycobacterial adjuvant: III. Lesions Eye Arch Ophthalmol. 1960;64(5):751–762.
   PubMed Web of Science ®Google Scholar
• Sunita A, Babiuk LA, George M. Mechanisms of action of adjuvants. Front Immunol. 2013;4(1):114–114.
   PubMed Web of Science ®Google Scholar
• Wang C, Liu P, Zhuang Y, et al. Lymphatic-targeted cationic liposomes: a robust vaccine adjuvant for promoting long-term immunological memory. Vaccine. 2014;32(42):5475–5483.
   PubMed Web of Science ®Google Scholar
• Jones S, Asokanathan C, Kmiec D, et al. Protein coated microcrystals formulated with model antigens and modified with calcium phosphate exhibit enhanced phagocytosis and immunogenicity. Vaccine. 2014;32(33):4234–4242.
   PubMed Web of Science ®Google Scholar
• Kool M, Petrilli V, De Smedt T, et al. Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J Immunol. 2008;181(6):3755–3759.
   PubMed Web of Science ®Google Scholar
• Elliott EI, Sutterwala FS. Initiation and perpetuation of NLRP3 inflammasome activation and assembly. Immunol Rev. 2015;265(1):35–52.
   PubMed Web of Science ®Google Scholar
• Tschopp J, Schroder K. NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production? Nat Rev Immunol. 2010;10(3):210–215.
   PubMed Web of Science ®Google Scholar
• Ronchi F, Basso C, Preite S, et al. Experimental priming of encephalitogenic Th1/Th17 cells requires pertussis toxin-driven IL-1β production by myeloid cells. Nat Commun. 2016;7:11541.
   PubMed Web of Science ®Google Scholar
• Eisenbarth SC, Colegio OR, O’Connor W, et al. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature. 2008;453(7198):1122–1126.
   PubMed Web of Science ®Google Scholar
• Marrack P, Mckee AS, Munks MW. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol. 2009;9(4):287–293.
   PubMed Web of Science ®Google Scholar
• Pazár B, Ea HK, Narayan S, et al. Basic calcium phosphate crystals induce monocyte/macrophage IL-1β secretion through the NLRP3 inflammasome in vitro. J Immunol. 2011;186(4):2495–2502.
   PubMed Web of Science ®Google Scholar
• Hayashi M, Aoshi T, Kogai Y, et al. Optimization of physiological properties of hydroxyapatite as a vaccine adjuvant. Vaccine. 2015;34(3):306–312.
   PubMed Web of Science ®Google Scholar
• Johansen P, Mohanan D, Martínez-Gómez JM, et al. Lympho-geographical concepts in vaccine delivery. J Control Release. 2010;148(1):56–62.
   PubMed Web of Science ®Google Scholar
• Platt AM, Randolph GJ. Dendritic cell migration through the lymphatic vasculature to lymph nodes. Adv Immunol. 2013;120(120):51–68.
   PubMed Web of Science ®Google Scholar
• Fifis T, Gamvrellis A, Crimeen-Irwin B, et al. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol. 2004;173(5):3148–3154.
   PubMed Web of Science ®Google Scholar
• Manolova V, Flace A, Bauer M, et al. Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol. 2008;38(5):1404–1413.
   PubMed Web of Science ®Google Scholar
• Reddy ST, Rehor A, Schmoekel HG, et al. In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J Control Release. 2006;112(1):26–34.
   PubMed Web of Science ®Google Scholar
• Smith DM, Simon JK, Baker JR Jr. Applications of nanotechnology for immunology. Nat Rev Immunol. 2013;13(8):592–605.
   PubMed Web of Science ®Google Scholar
• Zhao L, Seth A, Wibowo N, et al. Nanoparticle vaccines. Vaccine. 2014;32(3):327–337.
   PubMed Web of Science ®Google Scholar
• Banchereau J, Steinman RM. Dendritic cells and the control immunity. Nature. 1998;392(6673):245–252.
   PubMed Web of Science ®Google Scholar
• Shah RR, O’Hagan DT, Amiji MM, et al. The impact of size on particulate vaccine adjuvants. Nanomedicine. 2014;9(17):2671–2681.
   PubMed Web of Science ®Google Scholar
• Burgdorf S, Lukacskornek V, Kurts C. The mannose receptor mediates uptake of soluble but not of cell-associated antigen for cross-presentation. J Immunol. 2006;176(11):6770–6776.
   PubMed Web of Science ®Google Scholar
• Burgdorf S, Kautz A, Böhnert V, et al. Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation. Science. 2007;316(5824):612–616.
   PubMed Web of Science ®Google Scholar
• Flach TL, Ng G, Hari A, et al. Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity. Nat Med. 2011;17(4):479–487.
   PubMed Web of Science ®Google Scholar
• Reed SG, Orr MT, Fox CB. Key roles of adjuvants in modern vaccines. Nat Med. 2013;19(12):1597–1608.
   PubMed Web of Science ®Google Scholar
• Wang S, Mcdonnell EH, Sedor FA, et al. pH effects on measurements of ionized calcium and ionized magnesium in blood. Arch Pathol Lab Med. 2002;126(8):947–950.
   PubMed Web of Science ®Google Scholar
• Alberts B, Johnson A, Lewis J, et al. Molecular biology of the cell. Fifth edition. New York: Garland Science. 2007:1577–1579.
   Google Scholar
• Dorozhkin SV, Epple M. Biological and medical significance of calcium phosphates. ChemInform. 2002;41(47):3130–3146.
   Google Scholar
• Gupta RK, Rost BE, Relyveld E, et al. Adjuvant properties of aluminum and calcium compounds. Pharm Biotechnol. 1995;6:229–248.
   PubMedGoogle Scholar
• Rivera GP, Hühn D, Mercato LL, et al. Nanopharmacy: inorganic nanoscale devices as vectors and active compounds. Pharmacol Res. 2010;62(2):115–125.
   PubMed Web of Science ®Google Scholar
• Irvine DJ, Hanson MC, Rakhra K, et al. Synthetic nanoparticles for vaccines and immunotherapy. Chem Rev. 2015;115(19):11109–11146.
   PubMed Web of Science ®Google Scholar
• Toh MR, Chiu GNC. Liposomes as sterile preparations and limitations of sterilisation techniques in liposomal manufacturing. Asian J Pharm Sci. 2013;8(2):88–95.
   Google Scholar
• WHO good manufacturing practices for biological products. 2015. In: WHO Expert Committee on Biological Standardization. Sixty-sixth report. Geneva, World Health Organization, Technical Report Series, No. 999, annex 2. Replacement of Annex 1 of WHO Technical Report Series, No. 822.
   Google Scholar
• Guidelines on stability Evaluation of Vaccines. 2011. In: WHO Expert Committee on Biological Standardization. Fifty-seventh report. Geneva, World Health Organization, Technical Report Series, No. 962, annex 3.
   Google Scholar
• Guidelines on the nonclinical evaluation of vaccine adjuvants and adjuvanted vaccines. 2013. In: WHO Expert Committee on Biological Standardization. Sixty-fourth report. Geneva, World Health Organization, Technical Report Series, No. 987, annex 2.
   Google Scholar
• Guidelines for clinical evaluation of vaccines: regulatory expectations. 2016. In: WHO Expert Committee on Biological Standardization. Geneva, World Health Organization, Technical Report Series (in press). Revision of WHO TRS 924, Annex 1. Available from: http://www.who.int/biologicals/vaccines/en/
   Google Scholar
• European Medicines Agency. Guideline on adjuvants in vaccines for human use. London; 2005. EMEA/CHMP/VEG/134716/2004. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003809.pdf
   Google Scholar
• Ito A, Kawamura H, Miyakawa S, et al. Resorbability and solubility of zinc-containing tricalcium phosphate. J Biomed Mater Res A. 2002;60(2):224–231.
   Web of Science ®Google Scholar
• Ito A, Ojima K, Naito H, et al. Preparation, solubility, and cytocompatibility of zinc-releasing calcium phosphate ceramics. J Biomed Mater Res A. 2000;50(2):178–183.
   Web of Science ®Google Scholar
• Pele LC, Haas CT, Hewitt RE, et al. Synthetic mimetics of the endogenous gastrointestinal nanomineral: silent constructs that trap macromolecules for intracellular delivery. Nanomed-Nanotechnol. 2017;13(2):619–630.
   PubMed Web of Science ®Google Scholar
• Wang X, Li X, Ito A, et al. Rod-shaped and substituted hydroxyapatite nanoparticles stimulating type 1 and 2 cytokine secretion. Colloid Surface B. 2016;139:10–16.
   PubMed Web of Science ®Google Scholar
• Wang X, Li X, Onuma K, et al. Zn- and Mg-containing tricalcium phosphates-based adjuvants for cancer immunotherapy. Sci Rep-UK. 2013;3(29):2203–2203.
   PubMed Web of Science ®Google Scholar
• Xia L, Wang X, Yu S, et al. Mesoporous silica-calcium phosphate-tuberculin purified protein derivative composites as an effective adjuvant for cancer immunotherapy. Adv Healthc Mater. 2013;2(6):863–871.
   PubMed Web of Science ®Google Scholar
• Hanifi A, Fathi MH, Mir MSH. Effect of strontium ions substitution on gene delivery related properties of calcium phosphate nanoparticles. J Mater Sci-Mater M. 2010;21(9):2601–2609.
   PubMed Web of Science ®Google Scholar
• Kozlova D, Sokolova V, Zhong M, et al. Calcium phosphate nanoparticles show an effective activation of the innate immune response in vitro and in vivo after functionalization with flagellin. Virol Sinica. 2014;29(1):33–39.
   PubMedGoogle Scholar
• Knuschke T, Sokolova V, Rotan O, et al. Immunization with biodegradable nanoparticles efficiently induces cellular immunity and protects against influenza virus infection. J Immunol. 2013;190(12):6221–6229.
   PubMed Web of Science ®Google Scholar
• Sokolova V, Knuschke T, Kovtun A, et al. The use of calcium phosphate nanoparticles encapsulating Toll-like receptor ligands and the antigen hemagglutinin to induce dendritic cell maturation and T cell activation. Biomaterials. 2010;31(21):5627–5633.
   PubMed Web of Science ®Google Scholar
• Garçon N, Van MM. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev Vaccines. 2011;10(4):471–486.
   PubMed Web of Science ®Google Scholar
• Miller E, Andrews N, Stellitano L, et al. Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. BMJ. 2013;346:f794.
   PubMed Web of Science ®Google Scholar
• Seya T, Shime H, Takeda Y, et al. Adjuvant for vaccine immunotherapy of cancer-focusing on Toll-like receptor 2 and 3 agonists for safely enhancing antitumor immunity. Cancer Sci. 2015;106(12):1659–1668.
   PubMed Web of Science ®Google Scholar
• Marcus JK Calcium phosphate gels: U.S. Patent 2,605,229. 1952-7–29.
   Google Scholar
• Oyewumi MO, Kumar AZ. Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev Vaccines. 2010;9(9):1095–1107.
   PubMed Web of Science ®Google Scholar
• Yan S, Gu W, Xu ZP. Re-considering how particle size and other properties of antigen-adjuvant complexes impact on the immune responses. J Colloid Interf Sci. 2013;395(1):1–10.
   PubMed Web of Science ®Google Scholar
• Hiep K, Overwijk WW. Adjuvants for peptide-based cancer vaccines. J Immunother Cancer. 2016;4(1):56.
   PubMed Web of Science ®Google Scholar
• Saade F, Petrovsky N. Technologies for enhanced efficacy of DNA vaccines. Expert Rev Vaccines. 2012;11(2):189–209.
   PubMed Web of Science ®Google Scholar
• Graham FL, Van der Eb AJ. Transformation of rat cells by DNA of human adenovirus 5. Virology. 1973;54(2):536–539.
   PubMed Web of Science ®Google Scholar
• Truong-Le VL, Walsh SM, Schweibert E, et al. Gene transfer by DNA-gelatin nanospheres. Arch Biochem Biophys. 1999;361(1):47–56.
   PubMed Web of Science ®Google Scholar
• Qi HY, Daniels MP, Liu Y, et al. A cytosolic phospholipase A2 (cPLA2)-initiated lipid mediator pathway induces autophagy in macrophages. J Immunol. 2011;187(10):5286–5292.
   PubMed Web of Science ®Google Scholar
• Maitra A. Calcium phosphate nanoparticles: second-generation nonviral vectors in gene therapy. Expert Rev Mol Diagn. 2005;5(6):893–905.
   PubMed Web of Science ®Google Scholar
• Bisht S, Bhakta G, Mitra S, et al. pDNA loaded calcium phosphate nanoparticles: highly efficient non-viral vector for gene delivery. Int J Pharmaceut. 2005;288(1):157–168.
   PubMed Web of Science ®Google Scholar